Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK

被引:190
|
作者
Speakman, Mark [1 ]
Kirby, Roger [2 ]
Doyle, Scott [3 ,4 ]
Ioannou, Chris [3 ]
机构
[1] Musgrove Pk Hosp, Dept Urol, Taunton, Somerset, England
[2] Prostate Ctr, London, England
[3] GlaxoSmithKline, Uxbridge UB11 1BT, Middx, England
[4] Univ Oxford, Dept Publ Hlth, Oxford, England
关键词
BPH; burden of illness; quality of life; epidemiology; economics; LUTS; QUALITY-OF-LIFE; ENLARGED PROSTATE; MEDICAL-TREATMENT; PRIMARY-CARE; FOLLOW-UP; PREVALENCE; MEN; IMPACT; POPULATION; RETENTION;
D O I
10.1111/bju.12745
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) can be bothersome and negatively impact on a patient's quality of life (QoL). As the prevalence of LUTS/BPH increases with age, the burden on the healthcare system and society may increase due to the ageing population. This review unifies literature on the burden of LUTS/BPH on patients and society, particularly in the UK. LUTS/BPH is associated with high personal and societal costs, both in direct medical costs and indirect losses in daily functioning, and through its negative impact on QoL for patients and partners. LUTS/BPH is often underdiagnosed and undertreated. Men should be encouraged to seek medical advice for this condition and should not accept it as part of ageing, while clinicians should be more active in the identification and treatment of LUTS/BPH. To assess the burden of illness and unmet need arising from lower urinary tract symptoms (LUTS) presumed secondary to benign prostatic hyperplasia (BPH) from an individual patient and societal perspective with a focus on the UK. Embase, PubMed, the World Health Organization, the Cochrane Database of Systematic Reviews and the York Centre for Reviews and Dissemination were searched to identify studies on the epidemiological, humanistic or economic burden of LUTS/BPH published in English between October 2001 and January 2013. Data were extracted and the quality of the studies was assessed for inclusion. UK data were reported; in the absence of UK data, European and USA data were provided. In all, 374 abstracts were identified, 104 full papers were assessed and 33 papers met the inclusion criteria and were included in the review. An additional paper was included in the review upon a revision in 2014. The papers show that LUTS are common in the UK, affecting approximate to 3% of men aged 45-49 years, rising to > 30% in men aged >= 85 years. European and USA studies have reported the major impact of LUTS on quality of life of the patient and their partner. LUTS are associated with high personal and societal costs, both in direct medical costs and indirect losses in daily functioning. While treatment costs in the UK are relatively low compared with other countries, the burden on health services is still substantial. LUTS associated with BPH is a highly impactful condition that is often undertreated. LUTS/BPH have a major impact on men, their families, health services and society. Men with LUTS secondary to BPH should not simply accept their symptoms as part of ageing, but should be encouraged to consult their physicians if they have bothersome symptoms.
引用
收藏
页码:508 / 519
页数:12
相关论文
共 50 条
  • [21] Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
    Cavanaugh, Dana
    Urbanucci, Alfonso
    Mohamed, Nihal E.
    Tewari, Ashutosh K.
    Figueiro, Mariana
    Kyprianou, Natasha
    PROSTATE, 2024, 84 (05): : 417 - 425
  • [22] Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression
    Jiménez-Cruz, F
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (07) : 6 - 12
  • [23] Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
    Ueckert, Stefan
    Kedia, George T.
    Tsikas, Dimitrios
    Simon, Annika
    Bannowsky, Andreas
    Kuczyk, Markus A.
    WORLD JOURNAL OF UROLOGY, 2020, 38 (06) : 1423 - 1435
  • [24] The oral controlled absorption system (OCAS®):: The evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    Chapple, CR
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) : 20 - 22
  • [25] Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
    Stefan Ückert
    George T. Kedia
    Dimitrios Tsikas
    Annika Simon
    Andreas Bannowsky
    Markus A. Kuczyk
    World Journal of Urology, 2020, 38 : 1423 - 1435
  • [26] Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction
    Brock, Gerald
    Broderick, Gregory
    Roehrborn, Claus G.
    Xu, Lei
    Wong, David
    Viktrup, Lars
    BJU INTERNATIONAL, 2013, 112 (07) : 990 - 997
  • [27] The total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management: Introduction and conclusions
    Chapple, CR
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (07) : 1 - 5
  • [28] Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms
    McNicholas, Tom
    Kirby, Roger
    AMERICAN FAMILY PHYSICIAN, 2012, 86 (04) : 359 - 360
  • [29] Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Prevention or Retention?
    Schneider, Tim
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (11) : 696 - 701
  • [30] Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study
    Zhang, Weiyu
    Zhang, Xiaopeng
    Li, Haibin
    Wu, Feng
    Wang, Huanrui
    Zhao, Meishan
    Hu, Hao
    Xu, Kexin
    BMJ OPEN, 2019, 9 (06):